10-Q: Verrica Pharma Faces Going Concern Doubt Despite Revenue

Verrica Pharmaceuticals reports Q2 2025 results with increased collaboration revenue but acknowledges substantial doubt about its ability to continue as a going concern.

Summary

• Verrica Pharmaceuticals reports net income of $204,000 for the three months ended June 30, 2025, compared to a net loss of $17.19 million for the same period in 2024.
• License and collaboration revenue increased significantly to $8.17 million for the three months ended June 30, 2025, driven by an $8.0 million milestone payment from Torii.
• The company acknowledges substantial doubt about its ability to continue as a going concern due to an accumulated deficit of $316.6 million and cash and cash equivalents of $15.4 million as of June 30, 2025.
• A reverse stock split at a ratio of 1-for-10 was effected on July 24, 2025.
• The company is pursuing additional funding through equity offerings, debt financing, collaborations, and licensing arrangements to address its liquidity concerns.

Sentiment

Score: 4

Explanation: The filing contains both positive and negative elements. The company achieved net income for the quarter and increased collaboration revenue, but faces significant financial challenges and going concern uncertainty.

Positives

• Net income of $204,000 for the three months ended June 30, 2025, a significant improvement from the $17.19 million net loss in the same period of 2024.
• License and collaboration revenue increased to $8.17 million for the three months ended June 30, 2025, driven by an $8.0 million milestone payment from Torii.
• Selling, general, and administrative expenses decreased by $7.7 million for the three months ended June 30, 2025, due to lower commercial activity expenses.
• Research and development expenses decreased by $1.5 million for the three months ended June 30, 2025, related to decreased CMC and medical affairs costs.
• The company is in compliance with all applicable covenants under its Credit Agreement as of June 30, 2025.

Negatives

• The company has an accumulated deficit of $316.6 million as of June 30, 2025.
• The company has substantial doubt about its ability to continue as a going concern within one year after the date these financial statements are issued.
• Cash and cash equivalents decreased to $15.4 million as of June 30, 2025, from $46.3 million as of December 31, 2024.
• The company may be in default of its Credit Agreement in the near-term if the going concern qualification is not waived for future periods or if additional financing is not raised.
• Product revenue, net, decreased slightly to $4.5 million for the three months ended June 30, 2025, compared to $4.9 million for the same period in 2024.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional funding through equity offerings, debt financing, collaborations, and licensing arrangements.
• If the company is unable to raise capital when needed or on attractive terms, it may be forced to delay, reduce, or eliminate commercialization efforts and development programs.
• The company is subject to the general instructions of Form S-3 known as the "baby shelf rules," which limit the amount of funds it can raise through primary public offerings of securities.
• The company's Credit Agreement contains a financial covenant that it must maintain a liquidity of at least $10.0 million and that its financial statements not be subject to any qualification or statement which is of a "going concern" or similar nature.
• The company is involved in legal proceedings, including a putative class action complaint and stockholder derivative lawsuits, which could have a material adverse effect on its financial position.

Future Outlook

The company plans to secure additional capital through equity or debt financings, partnerships, or other sources to carry out its planned commercial and development activities. They expect to continue to incur significant expenses and operating losses for the foreseeable future.

Management Comments

• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures.
• Management believes the ultimate liabilities resulting from legal proceedings will not materially affect the company's financial position or its results of operations or cash flows.

Industry Context

Verrica Pharmaceuticals operates in the dermatology therapeutics market, which is characterized by high unmet needs and clinician-administered therapies. The company's focus on developing and commercializing treatments for skin diseases requiring medical intervention aligns with the broader industry trend of addressing specialized dermatological conditions.

Comparison to Industry Standards

• Assessing Verrica's performance against industry standards requires comparing its financial metrics and clinical development progress with similar-stage pharmaceutical companies.
• Comparable companies might include those focused on dermatology therapeutics, such as Cassiopea S.p.A., Timber Pharmaceuticals, and Journey Medical Corporation.
• Key benchmarks include revenue growth, R&D spending as a percentage of revenue, clinical trial success rates, and market penetration for approved products.
• Verrica's reliance on external funding and its current going concern status highlight the challenges faced by smaller biotech companies in sustaining operations and advancing clinical programs.

Legal Proceedings

• The company is involved in a putative class action complaint and stockholder derivative lawsuits related to alleged violations of federal securities laws and breaches of fiduciary duties.
• The Court granted the parties' joint stipulation to stay the Cohen derivative lawsuit and consolidate the Cohen and Cannon derivative lawsuits.
• The plaintiff in the Bonaccorso derivative lawsuit filed a notice voluntarily dismissing the action without prejudice.

Related Party Transactions

• Our Chief Executive Officer, Jayson Rieger, and our Chief Operating Officer, David Zawitz, are former employees of, and current consultants to, PBM Capital Group, LLC, an entity controlled by Paul B. Manning, a significant investor of the Company.

Stakeholder Impact

• Shareholders: The company's financial challenges and going concern uncertainty could negatively impact shareholder value.
• Employees: Potential cost-cutting measures or restructuring could affect employee job security.
• Customers: Continued availability of YCANTH (VP-102) may be affected by the company's ability to secure additional funding.
• Creditors: The company's ability to meet its debt obligations is dependent on securing additional financing.
• Suppliers: Potential delays or reductions in orders may occur if the company faces liquidity constraints.

Next Steps

• Continue commercialization of YCANTH (VP-102) for the treatment of molluscum contagiosum.
• Advance YCANTH (VP-102) for common warts through the Phase 3 Program with Torii.
• Report additional data on VP-315 for the treatment of BCC by the end of 2025.
• Pursue regulatory approvals for YCANTH (VP-102) for common warts and VP-315 for BCC.
• Secure additional capital through equity or debt financings, partnerships, or other sources.

Key Dates

Recommendation

Given the company's going concern status, high debt, and reliance on future capital raises, a sell recommendation is appropriate. The risk of dilution or inability to secure funding outweighs the potential upside from its products.

Keywords

Verrica Pharmaceuticals, YCANTH, VP-102, molluscum contagiosum, common warts, VP-315, basal cell carcinoma, financial results, SEC filing, going concern, Torii Pharmaceutical, OrbiMed